Protocol Ledger

NCT03860038 · Phase II · COMPLETED

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Interventional Phase II clinical trial protocol NCT03860038 sponsored by TJ Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-28 Enrollment: 113 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03860038
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)113 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03860038
Protocol FieldVerified Registry Value
NCT IdentifierNCT03860038
Consolidated Lead SponsorTJ Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment113 participants (ACTUAL)
Registered Start Date2019-01-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03860038
Hospital Research SiteLocationSite Profile
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Medical University Union HospitalFuzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI